EMEA-001103-PIP01-10-M03 - paediatric investigation plan
deferasirox
PIPHuman
Novartis Europharm Limited
Switzerland
Tel. +41 61 3241111
Fax +41 61 3248001
E-mail: paediatric.enquiries@novartis.com
P/0175/2016: EMA decision of 30 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for deferasirox (Exjade), (EMEA-001103-PIP01-10-M03)